Length of StayAcute DiseaseGermanyPostoperative PainDocumentationAnalgesiaAnalgesia, Patient-ControlledDiagnosis-Related GroupsEconomics, HospitalProspective Payment System
Dr. Assenmacher studies the role of a protein known as Apolipoprotein L1 (APOL1) in kidney diseases, particularly those connected to specific genetic variants. He investigates how the stability of APOL1 on cell surfaces can influence the development of new therapies for kidney issues. Additionally, he examines the impact of complex pain management strategies in surgical recovery, aiming to enhance pain control and resource allocation in hospitals for postoperative patients.
Key findings
Dr. Assenmacher's research showed that APOL1 molecules on the cell surface resist rapid breakdown, which is crucial for potentially developing new kidney disease treatments.
Patients receiving specialized pain therapy after surgery stayed an average of 2.5 days longer in the hospital than those who did not receive such therapy.
The additional cost to hospitals for patients receiving complex pain therapy was minimal, averaging around €200 more per case.
Frequently asked questions
Does Dr. Assenmacher study kidney diseases?
Yes, he focuses on how specific proteins, like APOL1, affect kidney diseases linked to genetic factors.
What treatments has Dr. Assenmacher researched?
He has researched new treatments for kidney diseases as well as complex pain management strategies for patients recovering from surgery.
Is Dr. Assenmacher's work relevant to patients recovering from surgery?
Yes, his studies on postoperative pain management directly benefit patients needing effective pain treatment after surgery.
Publications in plain English
APOL1 plasma membrane pools resist rapid protein degradation.
2026
Scientific reports
Höffken V, Alvermann L, Niggemeier D, Beul K, Nedvetsky P +5 more
Plain English This study looked at a protein called Apolipoprotein L1 (APOL1) and how its breakdown inside cells affects kidney diseases linked to genetic variants. The researchers found that APOL1 is quickly broken down by a cellular mechanism, but the pools of APOL1 on the cell surface are more stable. This stability at the surface is significant for developing new treatments for kidney diseases associated with APOL1.
Who this helps: Patients with APOL1-mediated kidney diseases and their doctors.
[What is the difference between patients with and without complex postoperative acute pain therapy?: An analysis of medical and economic characteristics].
2009
Schmerz (Berlin, Germany)
Fricke FU, Hertel N, Kubitz N, Assenmacher D, Schreder H
Plain English This study looked at patients who received specialized pain treatment after surgery and those who did not, using data from 372 hospitals. It found that patients who received the complex pain therapy stayed in the hospital for an average of 2.5 days longer and underwent more procedures, but the financial impact of this therapy on hospital revenue was minimal—about €200 more per case for patients with the therapy. Understanding these differences is important for improving pain management practices and hospital resource allocation.
Who this helps: This helps patients recovering from surgery who need better pain management.
Verena Höffken Laura Alvermann David Niggemeier Katrin Beul Pavel Nedvetsky Bernhard Ellinger Daniel Granado Hermann Pavenstädt Thomas Weide F-U Fricke
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.